Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes.

Otsuka, Tatsuhiko; Bär, Sarah; Losdat, Sylvain; Kavaliauskaite, Raminta; Ueki, Yasushi; Zanchin, Christian; Lanz, Jonas; Praz, Fabien; Häner, Jonas; Siontis, George C.M.; Zanchin, Thomas; Stortecky, Stefan; Pilgrim, Thomas; Windecker, Stephan; Räber, Lorenz (2021). Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American Heart Association, 10(23), e023129. American Heart Association 10.1161/JAHA.121.023129

Otsuka_JAmHeartAssoc_2021.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Background Complete revascularization reduces cardiovascular events in patients with acute coronary syndromes (ACSs) and multivessel disease. The optimal time point of non-target-vessel percutaneous coronary intervention (PCI) remains a matter of debate. The aim of this study was to investigate the impact of early (<4 weeks) versus late (≥4 weeks) staged PCI of non-target-vessels in patients with ACS scheduled for staged PCI after hospital discharge. Methods and Results All patients with ACS undergoing planned staged PCI from 2009 to 2017 at Bern University Hospital, Switzerland, were analyzed. Patients with cardiogenic shock, in-hospital staged PCI, staged cardiac surgery, and multiple staged PCIs were excluded. The primary end point was all-cause death, recurrent myocardial infarction and urgent premature non-target-vessel PCI. Of 8657 patients with ACS, staged revascularization was planned in 1764 patients, of whom 1432 patients fulfilled the eligibility criteria. At 1 year, there were no significant differences in the crude or adjusted rates of the primary end point (7.8% early versus 10.8% late, hazard ratio [HR], 0.72 [95% CI, 0.47-1.10], P=0.129; adjusted HR, 0.80 [95% CI, 0.50-1.28], P=0.346) and its individual components (all-cause death: 1.5% versus 2.9%, HR, 0.52 [95% CI, 0.20-1.33], P=0.170; adjusted HR, 0.62 [95% CI, 0.23-1.67], P=0.343; recurrent myocardial infarction: 4.2% versus 4.4%, HR, 0.97 [95% CI, 0.475-1.10], P=0.924; adjusted HR, 1.03 [95% CI, 0.53-2.01], P=0.935; non-target-vessel PCI, 3.9% versus 5.7%, HR, 0.97 [95% CI, 0.53-1.80], P=0.928; adjusted HR, 1.19 [95% CI, 0.61-2.34], P=0.609). Conclusions In this single-center cohort study of patients with ACS scheduled to undergo staged PCI after hospital discharge, early (<4 weeks) versus late (≥4 weeks) staged PCI was associated with a similar rate of major adverse cardiac events at 1 year follow-up. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02241291.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Department of Clinical Research (DCR)

UniBE Contributor:

Otsuka, Tatsuhiko, Bär, Sarah, Losdat, Sylvain Pierre, Kavaliauskaite, Raminta, Ueki, Yasushi, Zanchin, Christian, Lanz, Jonas, Praz, Fabien Daniel, Häner, Jonas, Siontis, Georgios, Zanchin, Thomas, Stortecky, Stefan, Pilgrim, Thomas, Windecker, Stephan, Räber, Lorenz


600 Technology > 610 Medicine & health




American Heart Association




Andrea Flükiger-Flückiger

Date Deposited:

03 Dec 2021 16:54

Last Modified:

20 Feb 2024 14:16

Publisher DOI:


PubMed ID:


Additional Information:

T. Otsuka und S. Bär contributed equally to this work.

Uncontrolled Keywords:

acute coronary syndrome multivessel coronary artery disease staged percutaneous coronary intervention





Actions (login required)

Edit item Edit item
Provide Feedback